Table 2.

Past 6 month receipt of alcohol treatment medications at baseline and follow-up by treatment group

Medication	Integrated Stepped Alcohol Treatment, N=63 No. (%)	Treatment as Usual, N=65 No. (%)	p value^a
Any alcohol treatment medication^a
Baseline	11 (17.46%)	10 (15.38%)	0·75
Week 4	20 (31.75%	4 (6.15%)	0.0002
Week 24	32 (50.79%)	17 (26.15%)	0·004
Week 52	16 (25.40%)	13 (20.00%)	0·47
Disulfiram
Baseline	0 (0·0%)	0 (0·0%)
Week 4	1 (1.59%)	0 (0.00%)	0·49
Week 24	2 (3·17%)	0 (0·0%)	0·24
Week 52	0 (0·0%)	0 (0·0%)	n/a
Acamprosate
Baseline	0 (0·0%)	0 (0·0%)
Week 4	1 (1.59%)	0 (0.0%)	0·49
Week 24	6 (9·52%)	0 (0.0%)	0·01
Week 52	0 (0%)	0 (0.0%)	n/a
Naltrexone
Baseline	0 (0.0%)	1 (1·54%)
Week 4	12 (19.1%)	0 (0.0%)	0.0002
Week 24	20 (31·75%)	5 (7·69%)	0.0007
Week 52	4 (6·35%)	5 (7·69%)	1·00
Topiramate
Baseline	0 (0·0%)	0 (0.0%)
Week 4	1 (1.59%)	0 (0.0%)	0·49
Week 24	0 (0.0%)	1 (1·54%)	1·00
Week 52	0 (0.0%)	1 (1·54%)	1·00
Baclofen
Baseline	3 (4·8%)	1 (1·54%)
Week 4	1 (1·59%)	0 (0.0%)	0·49
Week 24	1 (1·59%)	1 (1·54%)	1·00
Week 52	1 (1·59%)	1 (·54%)	1·00
Gabapentin
Baseline	9 (14·3%)	9 (13·9%)
Week 4	6 (9.5%)	4 (6.2%)	0·53
Week 24	12 (19·05%)	14 (21·54%)	0·73
Week 52	11 (17·46%)	12 (18·46%)	0·88

^a.

Based on receipt of disulfiram, acamprosate, naltrexone, topiramate, baclofen, and/or gabapentin.